November 17, 2015
Amgen showcases abstracts from Imlygic study at 12th International Congress of the Society for Melanoma Research
Amgen will present eight IMLYGIC (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck’s anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research …